Kaitlyn Andreano,Ching-yi Chang,Donald P. McDonnell,Stephanie L. Gaillard
申请号：
US15729320
公开号：
US20180098963A1
申请日:
2017.10.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
